Atrial natriuretic peptide is released primarily through atrial distension and haemodynamic disturbances, with potential contributions from humoral factors and changes in myocardial work.
In assessing the role that atrial natriuretic peptide (ANP) might have in the homeostasis of fluid volume and blood pressure, it is important to define the physiological and pathophysiological conditions that determine its release into the circulation. There is substantial evidence that ANP is released through atrial distension under a variety of conditions. There are also some indications that ANP may be released through humoral factors, although it is not clear whether this is a result of direct action on the myocytes or simply a result of ensuing haemodynamic changes. There is no evidence to suggest that ANP can be released through stimulation of efferent fibres innervating the atria, but it may be released as a result of changes in myocardial work and oxygen consumption. Plasma levels of ANP are elevated in several disease states and that release appears to be a result of the haemodynamic disturbances in those conditions.
A. J. Rankin (Sat,) conducted a review in Atrial natriuretic peptide release. Atrial natriuretic peptide is released primarily through atrial distension and haemodynamic disturbances, with potential contributions from humoral factors and changes in myocardial work.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: